www.fdanews.com/articles/101757-entremed-begins-pancreatic-cancer-study
EntreMed Begins Pancreatic Cancer Study
December 4, 2007
EntreMed has started a Phase II trial with MKC-1 in patients with advanced pancreatic cancer.
The multicenter study will determine the antitumor activity of orally administered MKC-1 in patients who have failed at least one chemotherapy regimen.
The study also will assess the safety, tolerability and overall median survival time of patients treated with the drug, EntreMed said.